Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 4/20 | 0.41 |
| ▸ | PYCR1 | P32322 | 4/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4228681 | 0.78 | CYP2A6 (0.47) | TAAR1HTR2ACYP2A6IDO1PYCR1 | |
| SCHEMBL5546173 | 0.75 | TAAR1 (0.50) | TAAR1HTR2ACYP2A6IDO1PYCR1 | |
| SCHEMBL9331371 | 0.74 | TRPA1 (0.52) | TAAR1IDO1MEN1KMT2A | |
| SCHEMBL3736025 | 0.74 | TAAR1 (0.48) | TAAR1HTR2ACYP2A6IDO1PYCR1 | |
| SCHEMBL1875 | 0.74 | MAOB (0.42) | TAAR1HTR2ACYP2A6IDO1PYCR1 | |
| SCHEMBL11690460 | 0.74 | IDO1 (0.46) | TAAR1CYP2A6IDO1PYCR1MEN1 | |
| SCHEMBL18245048 | 0.74 | TAAR1 (0.42) | TAAR1HTR2ACYP2A6IDO1PYCR1 | |
| SCHEMBL18770738 | 0.74 | PYCR1 (0.54) | TAAR1HTR2ACYP2A6IDO1PYCR1 | |
| SCHEMBL3633726 | 0.74 | MIF (0.52) | TAAR1IDO1PYCR1MAOB | |
| SCHEMBL2952783 | 0.74 | MIF (0.48) | TAAR1HTR2ACYP2A6IDO1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-4560749-A | ANTIBIOTICS, BACTERICIDES | ELI LILLY AND COMPANY (US) | 1985-12-24 | — | — | US | disclosed |
| US-4521598-A | 3-Azidocephalosporins | ELI LILLY AND COMPANY (US) | 1985-06-04 | — | — | US | disclosed |
| EP-0136177-A2 | 3-Azidocephalosporins as intermediates and novel antibacterial agents | ELI LILLY AND COMPANY (US) | 1985-04-03 | — | — | EP | disclosed |
| US-4045435-A | Preparation of cephalosporin ethers | ELI LILLY AND COMPANY (US) | 1977-08-30 | — | — | US | disclosed |
| US-3953438-A | Preparation of cephalosporin ethers | ELI LILLY AND COMPANY (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | TAAR1 364/4885HTR2A 4120/4885CYP2A6 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.